结合疗法与脏保护疗法:优化益处?
Sradha Kotwal1,2, Evan Perkovic3, Vlado Perkovic1,4
1The George Institute for Global Health, UNSW, Sydney, NSW 2052, Australia.
Current opinion in nephrology and hypertension
|September 28, 2023
概括
新的脏保护药物,包括SGLT-2抑制剂和MRA,对慢性脏病 (CKD) 患者,特别是糖尿病患者,显示出综合益处. 需要进一步的研究来优化用于个性化CKD治疗的组合疗法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 慢性病 (CKD) 管理已经通过新的保护剂取得了进展.
- 像SGLT-2抑制剂,MRA和GLP-1RA这样的药物提供了潜在的益处,特别是在糖尿病CKD.
- 本综述侧重于这些新型治疗剂的综合作用.
结论:
- 目前的证据表明,结合SGLT-2抑制剂和MRA可能对CKD患者有益.
- 组合疗法可能是管理CKD的适当的长期策略.
- 通过对最佳组合的进一步研究,个性化治疗策略对于改善CKD结果至关重要.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
21
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
21
Chronic Kidney Disease III: Interprofessional Care
28
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
28
Acute Kidney Injury V: Interprofessional Care
12
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
12
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Heart Failure Drugs: Diuretics
412
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
412


